Roth Capital Decreases Earnings Estimates for Flora Growth

Flora Growth Corp. (NASDAQ:FLGC) – Equities research analysts at Roth Capital reduced their Q2 2025 earnings per share (EPS) estimates for shares of Flora Growth in a report issued on Wednesday, May 14th. Roth Capital analyst W. Kirk now forecasts that the company will post earnings per share of ($0.06) for the quarter, down from their prior forecast of $0.02. The consensus estimate for Flora Growth’s current full-year earnings is ($0.93) per share. Roth Capital also issued estimates for Flora Growth’s Q3 2025 earnings at ($0.06) EPS, Q4 2025 earnings at ($0.06) EPS and FY2025 earnings at ($0.21) EPS.

Flora Growth Price Performance

Shares of FLGC opened at $0.66 on Friday. Flora Growth has a twelve month low of $0.42 and a twelve month high of $2.11. The company has a market capitalization of $12.83 million, a P/E ratio of -0.67 and a beta of 2.01. The firm has a 50 day moving average of $0.59 and a 200 day moving average of $0.93. The company has a quick ratio of 0.64, a current ratio of 1.02 and a debt-to-equity ratio of 0.43.

Flora Growth (NASDAQ:FLGC) last announced its quarterly earnings data on Tuesday, May 13th. The company reported ($0.04) EPS for the quarter, missing the consensus estimate of ($0.01) by ($0.03). Flora Growth had a negative net margin of 30.99% and a negative return on equity of 268.17%. The firm had revenue of $11.79 million for the quarter, compared to analysts’ expectations of $14.79 million.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. Virtu Financial LLC purchased a new position in Flora Growth in the 4th quarter worth about $43,000. AdvisorShares Investments LLC purchased a new position in shares of Flora Growth during the fourth quarter valued at approximately $73,000. Finally, Geode Capital Management LLC lifted its position in Flora Growth by 23.3% during the fourth quarter. Geode Capital Management LLC now owns 130,934 shares of the company’s stock valued at $135,000 after purchasing an additional 24,713 shares during the period. Hedge funds and other institutional investors own 36.01% of the company’s stock.

About Flora Growth

Flora Growth Corp., together with its subsidiaries, engages in the growth, cultivation, and development of medicinal cannabis and medicinal cannabis derivative products worldwide. It operates through three segments: House of Brands, Commercial and Wholesale, and Pharmaceuticals. The company cultivates, processes, and supplies medicinal-grade cannabis flower, and cannabis derived medical and wellness products.